Ascendis Pharma (ASND) Fundamental Analysis: Revenue, Earnings & Valuation

7.21 / 10

Outperform

Fundamental score is 7.2/10, rated Outperform. Strengths include strong Revenue‑MV, Cash‑MV and PB‑ROE, indicating solid revenue and cash relative to market value. Weak points are Asset‑MV and gross profit margin, suggesting asset efficiency and profitability concerns.

Analysis Checks(8/10)

Revenue-MV

Value-1.46

Score2/3

Weight45.95%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value98.03

Score2/3

Weight-4.52%

1M Return-1.06%

Inventory turnover ratio

Value0.32

Score2/3

Weight-5.27%

1M Return-1.21%

Gross profit margin (%)

Value86.82

Score0/3

Weight-27.40%

1M Return-7.24%

PB-ROE

Value8.91

Score3/3

Weight58.75%

1M Return9.74%

Income tax / Total profit (%)

Value-7.23

Score2/3

Weight5.01%

1M Return1.04%

Fixed assets turnover ratio

Value5.87

Score2/3

Weight-2.49%

1M Return-0.51%

Cost of sales ratio (%)

Value13.18

Score2/3

Weight-17.99%

1M Return-4.42%

Asset-MV

Value-0.55

Score0/3

Weight14.71%

1M Return2.69%

Cash-MV

Value-1.21

Score2/3

Weight33.27%

1M Return5.94%

Is ASND undervalued or overvalued?

ASND scores 7.21/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, -31.67% net margin, -53.31 P/E ratio, -74.66 P/B ratio, and 34.72% earnings growth, these metrics solidify its Outperform investment rating.